Immunology

Soluble CTLA4Ig Extends the Life of Adenovirus Transfection

Published in Gene Therapy Weekly, December 11th, 1995

Systemic coadministration of soluble CTLA4Ig with recombinant adenovirus extends adenoviral mediated gene expression.

One of the benefits of adenoviral-mediated gene transfection is its ability to transfect nonactive cells with great efficiency. One of its drawbacks is that the gene expression is transient, rarely lasting more than a few weeks.

One reason for the transient expression is that the host induces a cellular immune response against the transduced cells. In addition, a secondary genetic transfection via the same adenoviral vector is not possible due to host production of neutralizing antibodies against the adenovirus.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry